Erlotinib HCl (OSI-744) for Treatment of Nsclc CAS 183319-69

Erlotinib HCl (OSI-744) for Treatment of Nsclc CAS 183319-69-9

Email:kathelin@yccreate.com
Skype:live:kathelin_4
WhatsApp:+86-188 7222 0706

Erlotinib Hydrochloride is a small molecule inhibitor of the EGFR/HER-1 (human epidermal growth factor receptor) tyrosine kinase. Overexpression of the EGFR is present in many carcinomas, and inhibition of the activating kinase by Erlotinib provides a chemical intervention upon these systems. The inhibition of this tyrosine kinase effectively blocks EGFR activity but does not suppress tumor growth. When combined with 3,3'-diindolylmethane (sc-204624), efficacy against tumor proliferation was demonstrated.

Use in Cancer
Erlotinib hydrochloride is approved to be used alone or with other drugs to treat:

Non-small cell lung cancer (NSCLC).It is used as first-line treatment for metastatic NSCLC in patients with tumors that have certain epidermal growth factor receptor (EGFR) mutations.It is used for locally advanced or metastatic NSCLC in patients who have already been treated with chemotherapy.